Figure 4
From: Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects
Effect of rHuIL-12 or Placebo on rHuIL-12Rβ 2 Positivity and CD56 Mean Fluorescence Intensity in the Phase 1b Expansion Study. Flow cytometry was used to determine A) changes in the percentage of rHuIL-12Rβ2 positive NK and CD34+ cells in response to rHuIL-12 (12 μg) or placebo; and B) changes in CD56 mean fluorescence intensity on NK cells in response to dose of rHuIL-12 (12 μg) or placebo. NK cells were defined as CD45 + CD16 + CD56+ triple positive lymphocytes.